{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:20Z","timestamp":1788869240027,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,12,7]],"date-time":"2014-12-07T00:00:00Z","timestamp":1417910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,2]]},"abstract":"\n Aim<\/jats:title>\n \n To compare safety and efficacy of insulin glargine and liraglutide in patients with type 2 diabetes (\n T2DM<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This randomized, multinational, open\u2010label trial included subjects treated for\n T2DM<\/jats:styled-content>\n with metformin\u2009\u00b1\u2009sulphonylurea, who had glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) levels of 7.5\u201312%. Subjects were assigned to 24\u2009weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0\u20135.5\u2009mmol\/L or liraglutide, escalated to the highest approved clinical dose of 1.8\u2009mg daily. The trial was powered to detect superiority of glargine over liraglutide in percentage of people reaching HbA1c <7%.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The mean [standard deviation (s.d.)] age of the participants was 57 (9)\u2009years, the duration of diabetes was 9 (6)\u2009years, body mass index was 31.9 (4.2)\u2009kg\/m\n 2<\/jats:sup>\n and\n HbA1c<\/jats:styled-content>\n level was 9.0 (1.1)%. Equal numbers (\n n<\/jats:italic>\n \u2009=\u2009489) were allocated to glargine and liraglutide. Similar numbers of subjects in both groups attained an\n HbA1c<\/jats:styled-content>\n level of <7% (48.4 vs. 45.9%); therefore, superiority of glargine over liraglutide was not observed (p\u2009=\u20090.44). Subjects treated with glargine had greater reductions of HbA1c [\u22121.94% (0.05) and \u22121.79% (0.05); p\u2009=\u20090.019] and fasting plasma glucose [6.2 (1.6) and 7.9 (2.2) mmol\/L; p\u2009<\u20090.001] than those receiving liraglutide. The liraglutide group reported a greater number of gastrointestinal treatment\u2010emergent adverse events (p\u2009<\u20090.001). The mean (s.d.) weight change was +2.0 (4.0)\u2009kg for glargine and \u22123.0 (3.6)\u2009kg for liraglutide (p\u2009<\u20090.001). Symptomatic hypoglycaemia was more common with glargine (p\u2009<\u20090.001). A greater number of subjects in the liraglutide arm withdrew as a result of adverse events (p\u2009<\u20090.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Adding either insulin glargine or liraglutide to subjects with poorly controlled\n T2DM<\/jats:styled-content>\n reduces\n HbA1c<\/jats:styled-content>\n substantially, with nearly half of subjects reaching target levels of 7%.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12406","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T03:03:34Z","timestamp":1414724614000},"page":"170-178","source":"Crossref","is-referenced-by-count":50,"title":["Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes"],"prefix":"10.1111","volume":"17","author":[{"given":"D.","family":"D'Alessio","sequence":"first","affiliation":[{"name":"Department of Medicine University of Cincinnati College of Medicine Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2010U.","family":"H\u00e4ring","sequence":"additional","affiliation":[{"name":"Institute for Diabetes and Metabolic Disease Research University of T\u00fcbingen T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Charbonnel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Hospital La\u00ebnnec, University of Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de Pablos\u2010Velasco","sequence":"additional","affiliation":[{"name":"Dr Negrin Hospital, Las Palmas University Las Palmas de Gran Canaria Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Candelas","sequence":"additional","affiliation":[{"name":"Clinical Sciences and Operations, Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010P.","family":"Dain","sequence":"additional","affiliation":[{"name":"Global Diabetes Division, Sanofi Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Global Diabetes Division, Sanofi Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pilorget","sequence":"additional","affiliation":[{"name":"Medical Operations, Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yki\u2010J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Helsinki Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EAGLE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01918.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.13.S1.1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.621416"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1392"},{"key":"e_1_2_7_10_1","first-page":"e418","article-title":"Clinical inertia in patients with T2DM requiring insulin in family practice","volume":"56","author":"Harris SB","year":"2010","journal-title":"Can Fam Physician"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0331"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.48"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1472-y"},{"key":"e_1_2_7_15_1","first-page":"111","volume-title":"Handbook of Psychology and Diabetes: A Guide to Psychological Measurements in Diabetes Research and Practice","author":"Bradley C","year":"1994"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026485130100"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61267-7"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02941.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02619.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2011"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802418851"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.10.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2294"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12406","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:49:04Z","timestamp":1761864544000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,7]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/dom.12406"],"URL":"https:\/\/doi.org\/10.1111\/dom.12406","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725120153.793503458","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,7]]}}}